Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26

With strong financial backing and successful research, Wockhardt is poised for the launch of Zaynich, an antibiotic targeting high resistance levels globally. The company's strategic pricing and partnership approaches enhance its market penetration, setting the stage for a significant impact on the pharmaceutical industry.